Brief: Lyra Therapeutics Announces Restart Of Pivotal Phase 3 Enlighten Ii Clinical Trial Of Lyr-210 In Chronic Rhinosinusitis

Lyra Therapeutics

25/04/2023 13:50

Lyra Therapeutics Inc  LYRA.O :
    * LYRA THERAPEUTICS ANNOUNCES RESTART OF PIVOTAL PHASE 3
ENLIGHTEN
II CLINICAL TRIAL OF LYR-210 IN CHRONIC RHINOSINUSITIS
    * LYRA THERAPEUTICS INC - ENROLLMENT IN ENLIGHTEN I CLINICAL
TRIAL
REMAINS ON TRACK, WITH PIVOTAL DATA ANTICIPATED IN 1H 2024
    * LYRA THERAPEUTICS INC -  EXPECTS TO COMPLETE ENROLLMENT IN
THE
ENLIGHTEN II TRIAL IN THE SECOND HALF OF 2024

Source text for Eikon:  ID:nGNX3q7XRP 
Further company coverage:  LYRA.O